The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4302-4310

  Kim, Sang Doo ^a,b   Kim, Yoon Keun ^c   Lee, Ha Young ^a,b   Kim, You Sun ^c   Jeon, Seong Gyu ^c   Baek, Suk Hwan ^d   Song, Dong Keun ^e   Ryu, Sung Ho ^c   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; ANTIGEN; CYTOKINE; FORMYLPEPTIDE RECEPTOR AGONIST; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEPTIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHYLLYSYLTYROSYLMETHIONYLVALINE DEXTRO METHIONINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FORMYLPEPTIDE RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERICIDAL ACTIVITY; CECAL LIGATION AND PUNCTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG INHIBITION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNCTURE; SEPSIS; TH1 CELL; TH17 CELL; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INFECTION; MALE; MICE; MICE, INBRED ICR; RECEPTORS, FORMYL PEPTIDE; SEPSIS;

EID: 77958121745     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001310     Document Type: Article

References (53)

1. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891.
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
3. Aneja, R., and M. P. Fink. 2007. Promising therapeutic agents for sepsis. Trends Microbiol. 15:31-37.
4. Rangel-Frausto, M. S., D. Pittet, M. Costigan, T. Hwang, C. S. Davis, and R. P. Wenzel. 1995. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117-123.
5. Brun-Buisson, C. 2000. The epidemiology of the systemic inflammatory response. Intensive Care Med. 26 (Suppl 1): S64-S74.
6. Döcke, W. D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H. D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681.
7. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5:788-792.
8. Calandra, T., B. Echtenacher, D. L. Roy, J. Pugin, C. N. Metz, L. Hültner, D. Heumann, D. Männel, R. Bucala, and M. P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6:164-170.
9. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, R. E. Schmieg, Jr., J. J. Hui, K. C. Chang, D. F. Osborne, B. D. Freeman, J. P. Cobb, T. G. Buchman, and I. E. Karl. 2001. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166:6952-6963.
10. Wang, S. D., K. J. Huang, Y. S. Lin, and H. Y. Lei. 1994. Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 152:5014-5021.
11. Gogos, C. A., E. Drosou, H. P. Bassaris, and A. Skoutelis. 2000. Pro-versus antiinflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181:176-180.
12. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116.
13. Ulloa, L., and K. J. Tracey. 2005. The "cytokine profile": a code for sepsis. Trends Mol. Med. 11:56-63.
14. Le, Y., B. Li, W. Gong, W. Shen, J. Hu, N. M. Dunlop, J. J. Oppenheim, and J. M. Wang. 2000. Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol. Rev. 177:185-194.
15. Le, Y., J. J. Oppenheim, and J. M. Wang. 2001. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 12:91-105.
16. Bae, Y. S., Y. Kim, Y. Kim, J. H. Kim, P. G. Suh, and S. H. Ryu. 1999. Trp-Lys-Tyr-Met-Val-D-Met is a chemoattractant for human phagocytic cells. J. Leukoc. Biol. 66:915-922.
17. Le, Y., W. Gong, B. Li, N. M. Dunlop, W. Shen, S. B. Su, R. D. Ye, and J. M. Wang. 1999. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol. 163:6777-6784.
18. Bae, Y. S., S. A. Ju, J. Y. Kim, J. K. Seo, S. H. Baek, J. Y. Kwak, B. S. Kim, P. G. Suh, and S. H. Ryu. 1999. Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus via phospholipase D activation in human monocytes. J. Leukoc. Biol. 65:241-248.
19. Seo, J. K., S. Y. Choi, Y. Kim, S. H. Baek, K. T. Kim, C. B. Chae, J. D. Lambeth, P. G. Suh, and S. H. Ryu. 1997. A peptide with unique receptor specificity: stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils. J. Immunol. 158:1895-1901.
20. He, R., L. Tan, D. D. Browning, J. M. Wang, and R. D. Ye. 2000. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J. Immunol. 165:4598-4605.
21. Christophe, T., A. Karlsson, C. Dugave, M. J. Rabiet, F. Boulay, and C. Dahlgren. 2001. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276:21585-21593.
22. Bae, Y. S., Y. Kim, J. C. Park, P. G. Suh, and S. H. Ryu. 2002. The synthetic chemoattractant peptide, Trp-Lys-Tyr-Met-Val-D-Met, enhances monocyte survival via PKC-dependent Akt activation. J. Leukoc. Biol. 71:329-338.
23. Yan, J. J., J. S. Jung, J. E. Lee, J. Lee, S. O. Huh, H. S. Kim, K. C. Jung, J. Y. Cho, J. S. Nam, H. W. Suh, et al. 2004. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat. Med. 10:161-167.
24. Liu, D., B. X. Zeng, S. H. Zhang, and S. L. Yao. 2005. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm. Res. 54:464-470.
25. Wang, J., J. P. Silva, C. M. Gustafsson, P. Rustin, and N. G. Larsson. 2001. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl. Acad. Sci. USA 98:4038-4043.
26. Bae, Y. S., H. J. Yi, H. Y. Lee, E. J. Jo, J. I. Kim, T. G. Lee, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2003. Differential activation of formyl peptide receptor-like 1 by peptide ligands. J. Immunol. 171:6807-6813.
27. Baek, S. H., J. K. Seo, C. B. Chae, P. G. Suh, and S. H. Ryu. 1996. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J. Biol. Chem. 271:8170-8175.
28. Klein, C., J. I. Paul, K. Sauvé, M. M. Schmidt, L. Arcangeli, J. Ransom, J. Trueheart, J. P. Manfredi, J. R. Broach, and A. J. Murphy. 1998. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 16:1334-1337.
29. La, M., M. D'Amico, S. Bandiera, C. Di Filippo, S. M. Oliani, F. N. Gavins, R. J. Flower, and M. Perretti. 2001. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. FASEB J. 15:2247-2256.
30. Bae, Y. S., H. Y. Lee, E. J. Jo, J. I. Kim, H. K. Kang, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2004. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol. 173:607-614.
31. Hotchkiss, R. S., P. E. Swanson, B. D. Freeman, K. W. Tinsley, J. P. Cobb, G. M. Matuschak, T. G. Buchman, and I. E. Karl. 1999. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27:1230-1251.
32. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92:3007-3017.
33. Kim, Y. K., S. Y. Oh, S. G. Jeon, H. W. Park, S. Y. Lee, E. Y. Chun, B. Bang, H. S. Lee, M. H. Oh, Y. S. Kim, et al. 2007. Airway exposure levels of lipopolysaccharide determine type 1 versus type 2 experimental asthma. J. Immunol. 178:5375-5382.
34. Riedemann, N. C., R. F. Guo, and P. A. Ward. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-524.
35. Cohen, J. 1999. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. 55:212-225.
36. Dhainaut, J. F., A. Tenaillon, M. Hemmer, P. Damas, Y. Le Tulzo, P. Radermacher, M. D. Schaller, J. P. Sollet, M. Wolff, L. Holzapfel, et al. 1998. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit. Care Med. 26:1963-1971.
37. Fisher, C. J., Jr., J. F. Dhainaut, S. M. Opal, J. P. Pribble, R. A. Balk, G. J. Slotman, T. J. Iberti, E. C. Rackow, M. J. Shapiro, R. L. Greenman, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843.
38. Opal, S. M., C. J. Fisher, Jr., J. F. Dhainaut, J. L. Vincent, R. Brase, S. F. Lowry, J. C. Sadoff, G. J. Slotman, H. Levy, R. A. Balk, et al. 1997. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25:1115-1124.
39. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29 (7, Suppl) S121-S125.
40. Jeong, Y. I., I. D. Jung, C. M. Lee, J. H. Chang, S. H. Chun, K. T. Noh, S. K. Jeong, Y. K. Shin, W. S. Lee, M. S. Kang, et al. 2009. The novel role of platelet-activating factor in protecting mice against lipopolysaccharide-induced endotoxic shock. PLoS ONE 4: e6503.
41. Kox, W. J., T. Volk, S. N. Kox, and H. D. Volk. 2000. Immunomodulatory therapies in sepsis. Intensive Care Med. 26 (Suppl 1): S124-S128.
42. Dighe, A. S., D. Campbell, C. S. Hsieh, S. Clarke, D. R. Greaves, S. Gordon, K. M. Murphy, and R. D. Schreiber. 1995. Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 3:657-666.
43. Kox, W. J., R. C. Bone, D. Krausch, W. D. Döcke, S. N. Kox, H. Wauer, K. Egerer, S. Querner, K. Asadullah, R. von Baehr, and H. D. Volk. 1997. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch. Intern. Med. 157:389-393.
44. Berner, V., H. Liu, Q. Zhou, K. L. Alderson, K. Sun, J. M. Weiss, T. C. Back, D. L. Longo, B. R. Blazar, R. H. Wiltrout, et al. 2007. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13:354-360.
45. Gouwy, M., S. Struyf, P. Proost, and J. Van Damme. 2005. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 16:561-580.
46. Zhang, Q., M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, and C. J. Hauser. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464:104-107.
47. Chen, K., Y. Le, Y. Liu, W. Gong, G. Ying, J. Huang, T. Yoshimura, L. Tessarollo, and J. M. Wang. 2010. A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses. J. Immunol. 184:3331-3335.
48. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677-688.
49. Ferretti, S., O. Bonneau, G. R. Dubois, C. E. Jones, and A. Trifilieff. 2003. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharideinduced airway neutrophilia: IL-15 as a possible trigger. J. Immunol. 170:2106-2112.
50. Happel, K. I., M. Zheng, E. Young, L. J. Quinton, E. Lockhart, A. J. Ramsay, J. E. Shellito, J. R. Schurr, G. J. Bagby, S. Nelson, and J. K. Kolls. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170:4432-4436.
51. Stark, M. A., Y. Huo, T. L. Burcin, M. A. Morris, T. S. Olson, and K. Ley. 2005. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22:285-294.
52. Kolls, J. K., and A. Lindén. 2004. Interleukin-17 family members and inflammation. Immunity 21:467-476.
53. Flierl, M. A., D. Rittirsch, H. Gao, L. M. Hoesel, B. A. Nadeau, D. E. Day, F. S. Zetoune, J. V. Sarma, M. S. Huber-Lang, J. L. Ferrara, and P. A. Ward. 2008. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22:2198-2205.